Study Of Colchicine Resistance In Familial Mediterranean Fever
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Amount of colchicine measured in the first 2 cm of hair from the scalp of an FMF patient considered colchicine resistant or from pubic hair in patients with bald or colored hair, which corresponds to the average compliance of the last 2 months of intake
研究概览
简要总结
Five to 10% of familial mediterranean patients are considered colchicine-resistant (i.e. patients with a persistent inflammatory syndrome, despite taking the maximum tolerated dose of colchicine daily). The recommended treatment in this case is a subcutaneous anti-interleukin 1 biotherapy (anakinra or canakinumab). These treatments are expensive (1,000 to 12,000 euros/month).
However, for a patient to be considered colchicine-resistant, compliance with the treatment must be verified. Furthermore specific activation of the pyrin inflammasome by Clostrioides difficile toxin and the overrepresentation of these bacteria in the stools of our patients led us to systematically search for them in our resistant patients. The demonstration of the involvement of C. difficile in the imbalance of the disease has not yet been published.
The colchiresist study aim to better characterize colchicine-resistance by confirming good compliance to treatment with colchicine hair measurement and by looking for clostrioides infection or intestinal dysbiosis.
详细描述
Patients meeting the criteria for colchicine resistance will be included in a follow-up visit.
- Adherence to colchicine therapy will be assessed by the Girerd questionnaire completed by the patient at the inclusion visit.
- A blood test is performed including a haemogram, CRP and SAA, creatinine and proteinuria.
- a standard stool analysis on site to look for C. difficile toxin.
For research purposes, samples of:
- Stool.
- A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex, where the growth and integration are relatively constant to avoid variability.
- In patients with baldness or bleached hair only: pubic and/or axillary hair will be taken, The samples will then be processed without segmentation.
- Additional blood (5ml) and urine (2ml) samples for colchicine dosage. The patient's participation ends after this visit
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria Age ≥ 12 years with no upper age limit -Patients with familial Mediterranean fever (FMF) meeting international criteria for the disease (Livneh criteria) and carrying 2 pathogenic mutations in the MEFV gene.
- •Patients considered colchicine-resistant according to EULAR criteria reviewed by an expert consensus:
- •Persistence of signs of activity (at least one attack per month for at least 3 months) despite taking the maximum tolerated dosage of colchicine.
- •Persistence of a biological inflammatory syndrome after exclusion of other causes and despite taking a maximum tolerated dosage of colchicine.
- •Signature of an informed consent by the patient (or his parents if under 18 years of age)
- •Patients affiliated to a social security system
排除标准
- •Patients participating in another interventional trial
结局指标
主要结局
Amount of colchicine measured in the first 2 cm of hair from the scalp of an FMF patient considered colchicine resistant or from pubic hair in patients with bald or colored hair, which corresponds to the average compliance of the last 2 months of intake
时间窗: Through study completion, an average of 18 months
To assess 2-month compliance with colchicine in patients with FMF considered resistant via capillary drug dosage
次要结局
- Correlation between the amount of colchicine measured in the hair and the blood and urine levels of colchicine attesting to the last days' intake.(Through study completion, an average of 18 months)
- Correlation between capillary colchicine dosage and colchicine compliance assessed with the 6-item GIRERD(Through study completion, an average of 18 months)
- Testing for clostridioides difficile toxin B in colchicin-resistant patients(Through study completion, an average of 18 months)
- Composition of the fecal microbiota (search for an overrepresentation of clostridiae) in colchicine-resistant patients patients with colchicine resistance(Through study completion, an average of 18 months)
- Dosage of proinflammatory cytokines IL1, IL6, IL18, TNFa and il1Ra.(Through study completion, an average of 18 months)
- Percentage of patients for whom a prescription of anti-IL-1 biotherapy could have been avoided (i.e. poor compliance with Colchicine and/or Clostrioides Difficile infection)(Through study completion, an average of 18 months)